FDA grants Vitrase 5 years' exclusivity
The FDA has extended ISTA Pharmaceuticals' market exclusivity for hyaluronidase for injection (Vitrase) to 5 years from 3 years. The exclusivity will end May 5, 2009.
Latest News
California governor vetoes bill that would have reduced licensing requirements to perfom eye surgery
Visus Therapeutics expands ophthalmic drug development portfolio with acquisition of ViewPoint Therapeutics' assets
The survey, from The Larry A. Greene Center and the Primary Care Collaborative, found that the COVID-19 pandemic has had an adverse impact on the well-being of physicians.